Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis

• Published in: Journal of global antimicrobial resistance. Vol. 29; pp. 420 - 429
• Main Authors: Keikha, Masoud, Askari, Parvin, Ghazvini, Kiarash, Karbalaei, Mohsen
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.06.2022; Elsevier
• Subjects: Clarithromycin; Helicobacter pylori; Infection; Levofloxacin; Treatment; Infection; Levofloxacin; Clarithromycin; Treatment; Helicobacter pylori
• ISSN: 2213-7165; 2213-7173
• DOI: 10.1016/j.jgar.2021.10.019

•Recent studies have shown high rates of Helicobacter pylori eradication in patients treated with levofloxacin.•Eradication rate in patients receiving levofloxacin and clarithromycin was 75.2% and 66.3%, respectively.•Success of levofloxacin treatment was significantly greater than clarithromycin.•Interestingly, no side effects were observed in either treatment group.•Levofloxacin-based triple therapy is safer and more effective than clarithromycin-based triple therapy. Despite excessive resistance of Helicobacter pylori to clarithromycin among the Iranian population, clarithromycin-based therapy is still prescribed in Iran. Recent studies have shown high rates of H. pylori eradication in patients treated with levofloxacin. The main purpose of this study was to compare the effect of levofloxacin with clarithromycin on the eradication of H. pylori infection in the Iranian population. A comprehensive meta-analysis was done for relevant cohort studies and clinical trials to compare the therapeutic effects of levofloxacin and clarithromycin in the Iranian population. We pooled the data using odds ratio (OR) and corresponding 95% confidence interval (CI) to determine the clinical efficacy of levofloxacin versus clarithromycin to treat H. pylori infection. Heterogeneity and publication bias were also measured for the included studies. Thirteen studies were included in the quantitative synthesis. The eradication rate was significantly higher in patients receiving levofloxacin compared with clarithromycin (75.2% vs. 66.3%; OR = 1.76, 95% CI 1.40–2.20). Additionally, in the subgroup analyses it was confirmed that the cure rate was relatively higher in levofloxacin-treated cases. However, there was significant heterogeneity and publication bias, thus the results should be interpreted with caution. We found that the success of levofloxacin treatment was significantly higher than clarithromycin. Therefore, it is suggested that clarithromycin-based triple therapy be replaced by levofloxacin-based triple therapy in countries with high resistance to clarithromycin such as Iran. Nevertheless, the findings of this study need to be approved with a larger investigation on the Iranian population.